Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Genetically targeted clinical trials in parkinson’s disease: Learning from the successes made in oncology

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Cathepsin C Regulates Cytokine-Induced Apoptosis in β-Cell Model Systems

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. An Expanded Multi-Organ Disease Phenotype Associated with Mutations in YARS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Why Do Women with Eating Disorders Decline Treatment? A Qualitative Study of Barriers to Specialized Eating Disorder Treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Inpatient weight restoration treatment is associated with decrease in post-meal anxiety

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Why do women with eating disorders decline treatment? A qualitative study of barriers to specialized eating disorder treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Inpatient Weight Restoration Treatment Is Associated with Decrease in Post-Meal Anxiety

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Disturbances in the experiences of embodiment related to attachment, mentalization and self-objectification in anorexia nervosa

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area.

OriginalsprogEngelsk
Artikelnummer1529
TidsskriftGenes
Vol/bind12
Udgave nummer10
ISSN2073-4425
DOI
StatusUdgivet - okt. 2021

Bibliografisk note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

ID: 68497908